Ceftaroline Fosamil
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Ceftaroline fosamil: From Bacterial Infections to Rheumatoid Arthritis
One-Sentence Summary
Ceftaroline fosamil (brand name Zinforo) is a fifth-generation cephalosporin antibiotic, approved in the EU for acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP). The TxGNN model predicts it may be effective for Rheumatoid Arthritis, with a high model confidence score of 98.20%. However, this prediction is currently supported by 0 clinical trials and 0 relevant publications — and the mechanistic analysis strongly suggests this is a knowledge graph topology false positive rather than a genuine repurposing opportunity.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Acute bacterial skin and skin structure infections (ABSSSI); community-acquired bacterial pneumonia (CABP) |
| Predicted New Indication | Rheumatoid Arthritis |
| TxGNN Prediction Score | 98.20% |
| Evidence Level | L5 |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known pharmacology, ceftaroline fosamil is a β-lactam antibiotic whose mechanism centres on inhibition of bacterial cell wall synthesis via binding to penicillin-binding proteins (PBPs) — notably PBP2a of MRSA — thereby achieving broad-spectrum bactericidal activity against Gram-positive and selected Gram-negative pathogens.
Rheumatoid arthritis (RA) is an autoimmune condition driven by dysregulated T- and B-cell activation, synovial hyperplasia, and a pro-inflammatory cytokine cascade dominated by TNF-α and IL-6. There is no known pharmacological pathway by which PBP binding or cell wall synthesis inhibition would modulate autoimmune inflammation. Unlike tetracyclines or macrolides — which possess pleiotropic anti-inflammatory properties independent of their antimicrobial effects — β-lactam antibiotics have no established immunomodulatory mechanism relevant to RA pathophysiology.
The most plausible explanation for this high TxGNN score is an indirect knowledge graph (KG) connection: ceftaroline nodes linked to “septic arthritis treatment” or “joint infection” are topologically proximate to RA nodes within the graph, producing an artifactual high-confidence prediction. This is a known limitation of graph-based models when infectious disease nodes share structural proximity with inflammatory joint disease nodes. The prediction should be treated as a graph topology false positive pending any contrary experimental evidence.
Clinical Trial Evidence
Currently no related clinical trials registered for Ceftaroline fosamil in Rheumatoid Arthritis.
Literature Evidence
Currently no related literature available for Ceftaroline fosamil in Rheumatoid Arthritis.
Denmark Market Information
Ceftaroline fosamil currently holds no marketing authorisation active in the Danish market. The drug does hold a centralised EMA authorisation (Zinforo, EU/1/12/787/001-004) valid across the EU/EEA; however, it is not commercially distributed in Denmark at the time of this report.
| Marketing Authorisation Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| EU/1/12/787 (EMA — not actively marketed in DK) | Zinforo | Powder for concentrate for solution for infusion (600 mg) | Acute bacterial skin and skin structure infections; community-acquired bacterial pneumonia in adults |
Safety Considerations
Detailed Danish/TFDA SmPC warnings and contraindications were not available in this Evidence Pack. Please refer to the approved Summary of Product Characteristics (SmPC) for Zinforo — available via the EMA product page — for full safety information including hypersensitivity reactions, Clostridioides difficile-associated diarrhoea, haematological effects (haemolytic anaemia, neutropenia), and renal dose adjustment requirements.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN model assigns a high numerical score (98.20%), but this is almost certainly a knowledge graph topology artefact driven by proximity between infectious arthritis and inflammatory arthritis nodes — not a genuine pharmacological signal. Ceftaroline fosamil has no known mechanism relevant to autoimmune or degenerative joint disease, and the complete absence of supporting clinical trials or peer-reviewed literature confirms this assessment. Proceeding would not meet any scientific or regulatory standard for a repurposing programme.
To advance beyond Hold, the following would be required:
- Mechanistic evidence: Identification of a plausible biological mechanism linking PBP binding (or any ceftaroline off-target effect) to RA pathophysiology — currently none exists in the published literature.
- Experimental in vitro / in vivo data: Demonstration of anti-inflammatory activity in validated RA models (e.g., CIA mouse model, synoviocyte assays).
- KG audit: Review of the knowledge graph edge path generating this prediction to confirm or refute the suspected false-positive topology.
- Safety data: Retrieval and review of the full Zinforo SmPC, including immunological effects and any post-marketing signals relevant to inflammatory conditions.
- Clinical context clarification: The 2 PubMed publications retrieved (PMIDs 27530754 and 23312602) concern osteoarticular infection management — not RA or degenerative joint disease — and do not constitute evidence for any of the predicted non-infectious indications in this pack.
Research disclaimer: This report is for research reference only and does not constitute medical advice. All drug repurposing candidates require clinical validation before application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.